INTERVAL AFTER PROSTATE SPECIFIC ANTIGEN TESTING AND SUBSEQUENT RISK OF INCURABLE PROSTATE CANCER

Prostate Specific Antigen and Human Glandular Kallikrein 2 in Early Detection of Prostate Cancer

OPTIMAL PREDICTORS OF PROSTATE CANCER ON REPEAT PROSTATE BIOPSY: A PROSPECTIVE STUDY OF 1,051 MEN

PROSTATE CANCER DIAGNOSIS USING A SATURATION NEEDLE BIOPSY TECHNIQUE AFTER PREVIOUS NEGATIVE SEXTANT BIOPSIES

Relationship Among Initial Serum Prostate Specific Antigen, Prostate Specific Antigen Progression and Prostate Cancer Detection at Repeat Screening Visits

PREDICTORS OF SUBSEQUENT PROSTATE CANCER IN MEN WITH A PROSTATE SPECIFIC ANTIGEN OF 2.6 TO 4.0 NG/ML AND AN INITIALLY NEGATIVE BIOPSY

-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening Study

Prostate Specific Antigen Remains an Independent Predictor of Cancer at Prostate Biopsy in Black American Men But Not in White Men: Results from a Consecutive Series of 914 Men

Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range

Prostate MRI: Who, when, and how? Report from a UK consensus meeting

Gleason 6 Prostate Cancer: Translating Biology into Population Health

Predicting Prostate Biopsy Result in Men With Prostate Specific Antigen 2.0 to 10.0 ng/ml Using an Investigational Prostate Cancer Methylation Assay

The Impact of Recent Screening Recommendations on Prostate Cancer Screening in a Large Health Care System

PROSTATE SPECIFIC ANTIGEN BASED PROSTATE CANCER SCREENING: ACCUMULATING EVIDENCE OF EFFICACY BUT PERSISTENT UNCERTAINTY

Mass Screening for Prostate Cancer in Korea: A Population Based Study